» Articles » PMID: 19450635

Amplification of Immune Responses Against a DNA-delivered Idiotypic Lymphoma Antigen by Fusion to the B Subunit of E. Coli Heat Labile Toxin

Overview
Journal Vaccine
Date 2009 May 20
PMID 19450635
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The pentameric B-subunit of Escherichia coli heat-labile enterotoxin (EtxB) is not only highly immunogenic itself, but can also act as a potent adjuvant or carrier to increase immune responses to other antigens. In this study, we investigated the ability of EtxB to promote anti-tumor immune responses using a fusion DNA vaccine design. EtxB was genetically linked to a single chain Fv sequence derived from the idiotypic immunoglobulin antigen (Id) of the mouse BCL1 B-cell lymphoma. We found that the EtxB-BCL1scFv fusion protein with a specifically selected linker retained the ability to pentamerize and to bind the GM1 ganglioside. Immunization of mice with the pEtxB-BCL1scFv DNA construct generated high levels of Id-specific antibody and protected against lethal tumor challenge. The immuno-enhancing activities of EtxB were highly dependent on GM1 binding, since fusion constructs unable to pentamerize or to bind to GM1 were less effective. Thus, the EtxB fusion vaccine approach may be an attractive strategy to increase the potency of tumor vaccines.

Citing Articles

Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Meleshko A, Petrovskaya N, Savelyeva N, Vashkevich K, Doronina S, Sachivko N Hum Vaccin Immunother. 2017; 13(6):1-6.

PMID: 28272989 PMC: 5489279. DOI: 10.1080/21645515.2017.1285477.


Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Lopez-Requena A, Burrone O, Cesco-Gaspere M Front Oncol. 2012; 2:159.

PMID: 23162790 PMC: 3493989. DOI: 10.3389/fonc.2012.00159.


Immunotherapy for B-cell lymphoma: current status and prospective advances.

Hollander N Front Immunol. 2012; 3:3.

PMID: 22566889 PMC: 3342070. DOI: 10.3389/fimmu.2012.00003.


Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin.

Grassmann A, Felix S, dos Santos C, Amaral M, Seixas Neto A, Fagundes M Clin Vaccine Immunol. 2012; 19(5):740-5.

PMID: 22379066 PMC: 3346321. DOI: 10.1128/CVI.05720-11.


Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.

Alpizar Y, Chain B, Collins M, Greenwood J, Katz D, Stauss H Cancer Immunol Immunother. 2011; 60(8):1127-35.

PMID: 21479639 PMC: 11028423. DOI: 10.1007/s00262-011-0985-7.